K. J. Roozendaal - Concepedia

Author

K. J. Roozendaal

Also Known As

K J Roozendaal, K ROOZENDAAL, K Roozendaal, K. J. Roozendaal, K. Roozendaal, K.J. ROOZENDAAL, K.J. Roozendaal, Klaas J. Roozendaal, Klaas Roozendaal

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

OLVG European Organisation for Research and Treatment of Cancer The Netherlands Cancer Institute Radboud University Nijmegen University of Groningen

About

K. J. Roozendaal is an author at OLVG specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	22	1.4K
2	Health Sciences	4	4	257
3	Anesthesia	1	1	207
4	Cardiothoracic Surgery	1	1	102
5	Cell Biology	1	1	19

K. J. Roozendaal

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Aprotinin protects platelets against the initial effect of cardiopulmonary bypass Willem van Oeveren, Marcel P. Harder, K. J. Roozendaal, Journal of Thoracic and Cardiovascular Surgery ThrombosisCardiovascular DiseaseBlood PlateletMedicineCardiovascular Pharmacology	1990	374
Cell-Derived Microparticles Generated in Patients During Cardiopulmonary Bypass Are Highly Procoagulant Rienk Nieuwland, R.J. Berckmans, Reni C. Rotteveel-Eijkman, Circulation	1997	344
Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass Niels Jansen, Willem van Oeveren, L. van den Broek, Journal of Thoracic and Cardiovascular Surgery Cardiogenic ShockCardiac AnaesthesiaPulmonary CirculationMedicinePhysiology	1991	207
Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Giuseppe Giaccone, Otilia Dalesio, Gordon McVie, Journal of Clinical Oncology	1993	148
Standard Chemotherapy With or Without High-Dose Chemotherapy for Aggressive Non-Hodgkin's Lymphoma: Randomized Phase III EORTC Study Hanneke C. Kluin‐Nelemans, Vittorina Zagonel, A. Anastasopoulou, JNCI Journal of the National Cancer Institute	2001	146
First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group Robert Paridaens, P. Therasse, Luc Dirix, Journal of Clinical Oncology Breast OncologyGynecologyPharmacotherapyLine MbcMetronomic Chemotherapy	2004	108
Increased anticoagulation during cardiopulmonary bypass by aprotinin A.A.E.A. de Smet, Melvin Chang Njoek Joen, Willem van Oeveren, Journal of Thoracic and Cardiovascular Surgery ThrombosisCardiovascular DiseaseMedicineCardiopulmonary BypassPharmacotherapy	1990	108
Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass Marcel P. Harder, L. Eijsman, K. J. Roozendaal, The Annals of Thoracic Surgery Cardiac AnaesthesiaCardiothoracic SurgeryCardiovascular PharmacologyAprotinin ReducesSurgery	1991	102
Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial Marie José Kersten, Ruth L. Lange, Mathilde Smeets, Annals of Hematology Iron MetabolismDutch Multicenter TrialTransfusion MedicineHematologyClinical Trials	1996	92
Platelet preservation during cardiopulmonary bypass with aprotinin Ch. R. H. Wildevuur, L. Eijsman, K. J. Roozendaal, European Journal of Cardio-Thoracic Surgery	1989	79

Page 1